MAIA Biotechnology, Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
MAIA$1.09+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses: | ||
| Research and development expenses | $14,547,332 | $10,009,229 |
| General and administrative expenses | 9,722,354 | 6,947,981 |
| Total operating expenses | 24,269,686 | 16,957,210 |
| Loss from operations | (24,269,686) | (16,957,210) |
| Other income (expense): | ||
| Interest expense | — | (57) |
| Interest income | 313,954 | 318,367 |
| Australian research and development incentives | — | 79,954 |
| Grant income | 361,350 | — |
| Change in fair value of warrant liability | 1,198,210 | (6,682,758) |
| Loss on fair value of warrants over proceeds | — | (12,952) |
| Other income (expense) net: | 1,873,514 | (6,297,446) |
| Net loss | $(22,396,172) | $(23,254,656) |
| Net loss per share | ||
| Basic and diluted | $(0.70) | $(1.05) |
| Weighted average common shares outstanding basic and diluted | 32,114,608 | 22,197,517 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.